Hormone therapy and venous thromboembolism.
ABSTRACT Convincing data from randomized trials and observational studies have demonstrated a two- to threefold increased risk of venous thromboembolism (VTE) with the use of hormone replacement therapy (HRT) in post-menopausal women. This risk is highest in the first year of use, but an increased risk persists after the first year if HRT use is ongoing. The risk of VTE is increased for oral oestrogen alone, oral oestrogen combined with progestin and probably for transdermal HRT. There is an increase in both idiopathic and non-idiopathic VTE with HRT. Early evidence suggests an interaction of HRT with thrombophilic states such as the factor V Leiden mutation, resulting in a synergistic increase in the risk of VTE. There is also an increased risk of VTE with raloxifene and tamoxifen, but the effects of low-dose HRT and tibolone on VTE risk are less clear.
- SourceAvailable from: compoundingpharmacy.com.sg[Show abstract] [Hide abstract]
ABSTRACT: Different estrogens combined with various progestins, administered are used in hormone therapy (HT) for postmenopausal women. All these compounds, which do not have the same chemical structure and the same pharmacokinetic behavior as the bio-identicals hormones, estradiol 17β and progesterone, have intrinsic properties which can lead to tangible differences in therapeutic results. Recent biological and clinical data strongly suggest that the coronary and venous thromboembolic risk as well as the breast cancer risk attributed to HT use would not be the same according to the therapeutic scheme used. This article will briefly review the general principle of a true « hormone replacement therapy » and will discuss the recent data supporting the hypothesis that the cardiovascular and breast cancer risks might be lower with bio-identical hormones than with other therapeutic schemes.Gynécologie Obstétrique & Fertilité 05/2007; 35(5):388–397. DOI:10.1016/j.gyobfe.2007.02.013 · 0.58 Impact Factor
- Revista Brasileira de Hematologia e Hemoterapia 01/2009; 31(3). DOI:10.1590/S1516-84842009005000044
- Journal of Thrombosis and Haemostasis 03/2010; DOI:10.1111/j.1538-7836.2010.03839.x · 5.55 Impact Factor